Optical Interference in Coagulation Testing: Hemolysis, Lipemia, and Icterus

Optical coagulation analyzers allow laboratories to automate clot-based, chromogenic, and immunoturbidimetric assays on one platform. That flexibility also creates an important analytical question: can the instrument distinguish the intended reaction from the color or turbidity already present in the sample? Hemolysis, lipemia, and icterus can affect light transmission or absorbance, but the size and direction of the effect depend on the assay, wavelength, reagent, analyzer algorithm, and degree of interference.

A practical policy should avoid two extremes. Automatically rejecting every visibly abnormal plasma sample can delay testing and create unnecessary recollection. Reporting every result without assessing interference can release a number that does not represent the biological reaction. Laboratories need method-specific evidence, analyzer flags, reaction-curve review, and a documented response.

Understand what the analyzer measures

Optical clot detection follows a change in transmitted or scattered light as fibrin forms. Chromogenic methods measure the color generated when a substrate is cleaved. Immunoturbidimetric methods, including many D-Dimer and FDP applications, measure changes in turbidity as particles aggregate. A sample that is already colored or cloudy can alter the baseline signal, reduce the available measuring window, or distort the reaction curve.

Modern instruments may use multiple wavelengths, pre-reaction blanking, sample-quality indices, curve analysis, or alternative detection logic. These features reduce risk but do not make interference impossible. A flag such as “no clot,” “abnormal curve,” or “absorbance error” should be interpreted in the context of the method rather than treated as a simple instrument failure.

Hemolysis affects more than sample color

Hemolysis releases hemoglobin, which absorbs light and may interfere with optical detection. It can also reflect a difficult collection or handling process and may introduce biological effects from cellular contents. The impact is therefore not limited to a red appearance. Different PT, APTT, fibrinogen, D-Dimer, FDP, or antithrombin applications may respond differently to the same hemolysis level.

The laboratory should distinguish in-vitro hemolysis caused by collection or transport from possible in-vivo hemolysis, because recollection may solve only the first situation. Staff should avoid assuming that centrifugation or transferring clearer plasma removes the analytical issue. Hemoglobin remains in the plasma even when cells are no longer visible.

Lipemia changes turbidity and sample handling

Lipemic plasma scatters light and may produce a high optical baseline. Immunoturbidimetric assays can be particularly challenging because turbidity is also part of the intended reaction. Clot-based optical assays may fail to identify a reliable endpoint, while mechanical clot detection may be less affected by sample color but still subject to other limitations.

Severe lipemia can also create pipetting or volume issues and may be unevenly distributed if the sample is not handled consistently. Any clearing procedure must be validated for the assay. Removing the lipid layer, using high-speed centrifugation, or transferring plasma can also remove or redistribute analytes. A procedure that improves visual clarity is not automatically analytically neutral.

Icterus can overlap with assay wavelengths

Icteric samples contain increased bilirubin and have a yellow-to-brown color that may overlap with wavelengths used by optical assays. The effect may vary between clot-based, chromogenic, and immunoturbidimetric methods. For chromogenic antithrombin or other color-producing assays, the baseline and reaction wavelength deserve specific evaluation.

Visual inspection alone is inconsistent, especially under different lighting. Automated sample indices can improve standardization, but their thresholds must be linked to the exact assay application. A universal icterus index applied to every test on an analyzer may be convenient but insufficient.

Build an assay-specific interference map

The laboratory should maintain accessible information for each assay: the manufacturer’s evaluated interference levels, analyzer flags, locally verified limits where required, alternate methods, and reporting action. The map should distinguish PT, APTT, fibrinogen, TT, D-Dimer, FDP, and antithrombin because their optical principles and result sensitivities differ.

For a new reagent-analyzer application, interference verification can use paired samples prepared across defined hemolysis, lipemia, or bilirubin levels. The design should compare affected and control samples while maintaining the analyte concentration as consistently as possible. Acceptance criteria must be defined before reviewing results and should reflect analytical performance near important reporting regions.

Review the reaction curve before choosing a response

A single numerical result does not show whether the analyzer observed a normal reaction. Curve shape, baseline, signal amplitude, endpoint, and instrument flags provide useful evidence. An unexpected flat, noisy, biphasic, or truncated curve may indicate that optical interference or another sample issue affected detection.

If the analyzer provides an alternate wavelength or mechanical channel, the laboratory should follow validated switching rules. Manual clot detection is not automatically a reference method and can introduce observer variation. Repeating the same sample on the same optical channel without changing the condition may reproduce the problem rather than resolve it.

Use a defined result pathway

A practical procedure may allow reporting when the sample index is below the validated interference limit and the reaction curve is acceptable. Results near or above the limit may require dilution where validated, an alternate method, recollection, a qualified comment, or cancellation according to laboratory policy. The pathway should also define who reviews flagged results.

Comments should be factual and method-specific. They should not imply a patient diagnosis or overstate certainty. When a result cannot be reported, the laboratory should communicate whether the limitation is sample quality, optical interference, measuring range, or another analytical condition so that the next action is clear.

Support customers with evidence, not generic claims

Distributors and reagent manufacturers should provide interference data for the intended analyzer application, including how samples were prepared, concentrations tested, acceptance criteria, and observed bias. Statements such as “not affected by hemolysis” are rarely sufficient without a defined level and method.

For OEM and localization projects, interference testing belongs in application development and product documentation. Raw material or formulation changes can alter optical background, reaction kinetics, or tolerance to sample color. Local technical teams should be trained to collect indices, flags, curves, lots, settings, and comparison results before escalating a complaint.

Hemolysis, lipemia, and icterus are visible reminders that a coagulation result is produced by both biology and measurement. Method-specific limits, disciplined curve review, and a clear reporting pathway help laboratories manage optical interference without unnecessary rejection or unsupported reporting.